Payment overview · 2025
General Payments
$137.55
7 reported records · 6 companies
Healthcare provider profile · identity verified
Leandre W. Odom, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW IBERIA, LA · NPI 1003846809
Verified facts
What the public records show
CMS Open Payments records show Leandre W. Odom, D.O. received $137.55 in general payments during 2025 across 7 reported records.
Lilly USA, LLC accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.92 | 32.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.21 | 15.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.84 | 15.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.33 | 14.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.74 | 12.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.51 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.55 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 368 | 104 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 309 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 292 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 253 | 34 |
| Gabapentin | Gabapentin | 238 | 45 |
| Metformin Hcl Er | Metformin Hcl | 230 | 57 |
| Tramadol Hcl | Tramadol Hcl | 218 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 26 |
| Montelukast Sodium | Montelukast Sodium | 188 | 48 |
| Omeprazole | Omeprazole | 178 | 26 |
| Irbesartan | Irbesartan | 167 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 39 |
| Desloratadine | Desloratadine | 146 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 39 |
| Metformin Hcl | Metformin Hcl | 118 | 25 |
| Glimepiride | Glimepiride | 107 | 30 |
| Alprazolam | Alprazolam | 105 | 13 |
| Jardiance | Empagliflozin | 101 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 37 |
| Furosemide | Furosemide | 92 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 91 | 21 |
| Buspirone Hcl | Buspirone Hcl | 90 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 26 |
| Linzess | Linaclotide | 85 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 25 |
| Ibuprofen | Ibuprofen | 83 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 15 |
| Losartan Potassium | Losartan Potassium | 78 | 21 |
| Baclofen | Baclofen | 74 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | suppressed |
| Prednisone | Prednisone | 72 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 18 |
| Valsartan | Valsartan | 71 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 14 |
| Naproxen | Naproxen | 61 | 20 |
| Ozempic | Semaglutide | 61 | suppressed |
| Tradjenta | Linagliptin | 61 | suppressed |
| Methocarbamol | Methocarbamol | 59 | 23 |
| Trulicity | Dulaglutide | 59 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 24 |
| Meloxicam | Meloxicam | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Famotidine | Famotidine | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Carvedilol | Carvedilol | 43 | 12 |
| Celecoxib | Celecoxib | 43 | 16 |
| Diazepam | Diazepam | 43 | suppressed |
| Lisinopril | Lisinopril | 41 | 13 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 37 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Phenobarbital | Phenobarbital | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 20 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Indomethacin | Indomethacin | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 15 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.55 · 7 records | Lilly USA, LLC | FARXIGA, IBSRELA, JARDIANCE, OFEV, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error